Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
about
Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cellsTumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers.Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancerImmunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survivalCD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma.Immunological basis in the pathogenesis and treatment of bladder cancerCancer/testis antigens and urological malignanciesCancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implicationsMAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptidesDemethylation of MAGE promoters during gastric cancer progression.Immunotherapeutic strategies for high-risk bladder cancer.Immunotherapeutic strategies for bladder cancer.Expression profile of SPACA5/Spaca5 in spermatogenesis and transitional cell carcinoma of the bladder.An essential role for decorin in bladder cancer invasiveness.The biology of cancer testis antigens: putative function, regulation and therapeutic potentialGeneration of potent cytotoxic T lymphocytes against in male patients with non-muscle invasive bladder cancer by dendritic cells loaded with dying T24 bladder cancer cells.
P2860
Q24804892-D046EC7B-A319-4CC4-8E7F-FD1E7E4593C9Q33555751-6744AF53-01A9-4087-B3A9-0DD03B888250Q33788100-0DBFCB0B-05EB-4F34-88C0-76CAB4C98BE9Q33819820-15164307-1F28-40DD-9958-EB1097D3EF0CQ35144956-61596695-3890-4B61-BF97-422FD50AE6F6Q35676736-2EC9D8BD-512E-4FD5-B492-2C2A96A6E716Q36075245-627DB1B5-4186-465F-BD75-D1622BA93226Q36260118-15748399-C619-42FB-941B-DE0A7039E3DAQ36337004-54C7BA83-B3ED-498A-AB3A-9C81297EDF7BQ36623761-5E2EB243-A344-4C16-9C6E-E6472ADA6299Q36695328-F33CA5EE-0D16-4165-BA24-A016C337EFCEQ36696751-C9D1B305-2409-4784-8FA3-F13036C28714Q36768976-2B18AE29-3EF0-42BE-84B2-04C42046CA85Q36977628-700B4204-27F4-4E59-A704-FFA1386BEBF5Q37407149-547160D3-0A0C-457B-970F-66FC438ADB3EQ37557168-6FAA5B39-3759-4985-A3F9-62E57FF93AEBQ37849976-CBC94888-A108-488C-9798-84EA6F98C50CQ38713382-3669EC9B-79AF-4D55-B907-5CB43669D4DA
P2860
Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Immunotherapy of bladder cance ...... n-A24-specific MAGE-3 peptide.
@en
type
label
Immunotherapy of bladder cance ...... n-A24-specific MAGE-3 peptide.
@en
prefLabel
Immunotherapy of bladder cance ...... n-A24-specific MAGE-3 peptide.
@en
P2093
P1476
Immunotherapy of bladder cance ...... n-A24-specific MAGE-3 peptide.
@en
P2093
Horiguchi Y
Nakamura K
Nishiyama T
Tachibana M
Takesako K
P407
P577
2001-01-01T00:00:00Z